Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Imaging Tech to Improve Diagnosis and Treatment of Skin Cancers

By LabMedica International staff writers
Posted on 17 Oct 2025

Skin cancer is the most common malignancy worldwide, and accurately assessing tumor invasion or treatment response remains a major clinical challenge. More...

Current imaging methods, such as confocal microscopy and optical coherence tomography, provide high-resolution images only at shallow tissue depths, while deeper imaging approaches like ultrasound often lack contrast or precision. Now, a new non-invasive optical imaging method promises to overcome these limitations by providing deeper, clearer views of biological tissues.

The technology, being developed by researchers at the University of Arizona (Tucson, AZ, USA), is termed Synthetic Wavelength Imaging (SWI) and uses two distinct illumination wavelengths to generate a virtual “synthetic” wavelength. This longer wavelength allows light to penetrate deeper into tissue with minimal scattering while retaining the high contrast from the original wavelengths, enabling detailed visualization of skin cancers.

The project is specifically focusing on nonmelanoma skin cancers such as basal cell and squamous cell carcinoma, which present varied lesion depths and invasion patterns. If successful, the SWI method will provide the tunable imaging capabilities necessary to accurately assess tumor characteristics and monitor treatment. The researchers aim to translate these imaging advances into clinical practice to better define tumor margins and monitor treatment progress in real time.

The improved visualization may help detect invasive lesions earlier and personalize non-invasive therapy plans. In addition to skin cancer, the wide tunability of the synthetic wavelength could enable imaging of other tissues such as the breast or human brain, expanding its potential to other diagnostic and surgical applications.

"Our goal is to translate these imaging advances into clinical practice," said Curiel-Lewandrowski, principal investigator. "If we can detect invasive lesions earlier, define tumor margins more precisely, and monitor response to non-invasive treatments in real time, we can maximize the effectiveness of emerging therapeutic approaches. This will also allow us to tailor intervention length and dosing individually to each patient."

Related Links:
University of Arizona


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.